Erasca, Inc.
A clinical-stage biopharmaceutical company developing medicines for cancers driven by the RAS/MAPK pathway, one of the most frequently mutated signaling routes in human tumors. Founded in San Diego in 2018, its name blends "RAS" with "era," reflecting a mission to open a new era in treating RAS-driven cancers. The company is building a pipeline of experimental drugs aimed at this stubborn family of cancer-causing proteins.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Jonathan E. Lim | 13G/APassive | 10.4% | 36.97M | Aug 14, 2026 |
| Conyee T. Lim | 13G/APassive | 5.6% | 19.46M | Aug 14, 2026 |
| City Hill, LLC | 13G/APassive | 3.7% | 12.90M | Aug 14, 2026 |
| T. Rowe Price Investment Management, Inc. | 13G/APassive | 6.8% | 21.22M | May 15, 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 13G/APassive | 5.3% | 16.38M | May 15, 2026 |
| VHCP Co-Investment Holdings III, LLC | 13G/APassive | 5.3% | 16.38M | May 15, 2026 |
| Venrock Healthcare Capital Partners EG, L.P. | 13G/APassive | 5.3% | 16.38M | May 15, 2026 |
| VHCP Management III, LLC | 13G/APassive | 5.3% | 16.38M | May 15, 2026 |
| VHCP Management EG, LLC | 13G/APassive | 5.3% | 16.38M | May 15, 2026 |
| Nimish Shah | 13G/APassive | 5.3% | 16.38M | May 15, 2026 |